Deepak Nitrite Ltd conference call was today at 12:00 clock
"Expects to grow at about 25% growth in next couple of years"
Here are the key takeaways Thread
Business Updates:
β’ Growth is from the segment of specialty chemical and Phenolics.
β’ Demand and utilization returning to pre-covid level.
β’ Recovery in domestic economic market (around 31% growth), with export revenue growth by 12.9%
β’ Segmental result shown in image
Development:
β’ Land development activity has commenced at the newly acquired site measuring 127 acres at Dahej.
β’ Balance Sheet of the company remains strong.
β’ Growth in Phenolics was majorly because of volume growth. Deepak Phenolics at D/E ratio of 0.28 times.
"Expects to grow at about 25% growth in next couple of years"
Here are the key takeaways π§΅π
Business Updates:
β’ Sales and PAT grewt by 89% and 50.8% YoY
β’ Green field plant expansion in Karnataka
β’ Brown field CTP line to be set up in UAE and a BOPET line in Poland
β’ Started trial runs in Poland plans.
β’ Mgmt expects largest volume gwth with completion of expansion
β’ Margin and Packing business were but lower in QoQ basis, because of reversal of decline in raw material prices which was there in Q1 and Q2.
β’ Hence the margins on these front were lower compare to Q1 and Q2.
β’ Focus remains now on value added products.
β’ Speed of filing products has been increased. Filed 5 new DMFs β 3 in US and 2 in EU
β’ Currently ramping up the facility in VIZAG with strong customer attraction, and will be commercialized as planned in Q3
β’ VIZAG EBIDTA growth guidance changed to 40%+ YoY
β’ Growth Driver: Broad based growth in other products and Vizag.
β’ PLI: Company has filed Mysore for PLI scheme for 1 molecule.
β’ Technology: Company is about to complete its 2 out of 3 technology, which will enhance efficiency for Solara.
Shankara Building Products concall was today at 11:30 AM π
Here are the Key takeaways from the earning call ππ§΅
Business Updates:
β’ Q3 has seen uptick in the demand and co. is at its 80% of the pre-covid sales.
β’ There has been pick up in all the segment.
β’ Affordable Housing Segment has seen growth in the driver of business.
Segments
β’ Retail sector has seen 14% of the revenue growth. Revenue contribution 60%.
β’ Company has decreased the number of stores, as co. believes that they can work more efficiently with less number of stores.
β’ Avg ticket size of the company has been increased. (See image)
Tata Products continuous to remain at strong growth and expects to launch new product soon.
Here are the Key takeaways from the earning call π§΅π
Strengthening core business-
β’ Advertsised in IPL and KBC, branding Tata Gold.
β’ Launched product poha
Innovation
β’ Lacunhed Kambucha and and continue growing brand in Tea and Coffee.
β’ Laucnh Tata Gold Coffee in America.
New engines of growth presented in image
Strengthening Synergies:
β’ Common distributors in India for better supply chain.
β’ Running toward wholesale model to retail model.
β’ Company has increased the outlet expansion, and have worked on improving the transport and warehousing management system
Hope customer book of Neuland to remain as booked and full just like today's conference callπ
Here are the Key takeaways from the earning callπ
Business Updates:
β’ Price growth drivers were Levetiracetam and Mirtazapine.
β’ Commercialization of Unit 3 has begun and 2 API have been shipped in.
β’ Neuland has filed Donepezil based with USDFA.
Q from @unseenvalue sir: Growth opportunity in Peptide (esp. on generic)
β’ Involved in many molecule discovery in generic side
β’ Co. has seen value on generic capacity, GDS being continuous play for the company
β’ Co. may have partnership for generic side of business as well.
"We are witnessing a huge investment in manufacturing sector consequent to domestic demand growth and localization under atma Nirbhar bharat programme."
Here are the concall key takeaways π
π§΅π
Financial highlights
- Business continued to stage and encouraging recovery and has almost scaled up to last year's qiarter level
- An improved customer buying sentiment continued in Q3 supported by more stable business environment
- Casflows remain stable
- Revenue from operations recovered 90.9%
- Ebitda was Rs. 81.56 crores. Driven by improved profitability across all segments
- Tax expense was Rs. 12.96 crores
- Net profit grew 86% compared to last year quarter.
Business Updates:
β’ Contributor for this year was the robust product basket.
β’ Formulation contribution of 39%.
β’ See product filing in image
β’ Continue investing in infrastructure.
β’ De-bottle-necking the plant continuous to remain online.
β’ Expanding capacities in key API.
β’ See the segment revenue breakup in the image.
β’ Dedicated a special plant location for CRAMS Facility.
β’ Richcore will be named as Lauruas Bio and acquired 100% in Richcore
Business Updates:
β’ Closed with 300 customer.
β’ Plants started in phases. Recovery of textile sector in pandemic was slow.
β’ Price of certain products has reach to pre-covid level.
β’ With new capacity company is going to do filaments yarn and spurt yarn.
β’ Bio-degradable fibre has capable of bio-degrade in land and ocean within an year.
β’ company will be also starting short cut fibre which have application in cement industry.
β’ Company is also working on re-cycle footprint which will have edge in the market over long term.
Munger: What was interesting was how talented they were and then also got in so much trouble. It also demonstrates general system of finance involving derivatives is irresponsible.
Warren: Here you had extremely experienced people operating with their own money.
β’ They went broke. Why do people risk losing something very important to gain something thatβs totally unimportant? The added money has no utility whatsoever.